TDMS Study 96007-04 Pathology Tables
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:26
FINAL#4/RATS
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFDIOXINMIX
Lock Date: 09/12/01
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:26
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 98 98 98 98 98
Early Deaths
Moribund Sacrifice 26 25 22 25 33
Natural Death 11 5 6 4 10
Dosing Accident 1 1 2
Survivors
Terminal Sacrifice 16 23 24 23 8
Animals Examined Microscopically 53 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (53) (52) (53) (53) (51)
Carcinoma 1 (2%)
Intestine Large, Rectum (52) (53) (53) (53) (52)
Polyp Adenomatous 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Intestine Large, Cecum (51) (53) (53) (53) (51)
Intestine Small, Duodenum (52) (53) (53) (53) (52)
Carcinoma 1 (2%)
Intestine Small, Jejunum (52) (53) (53) (53) (50)
Leiomyosarcoma 1 (2%) 1 (2%)
Intestine Small, Ileum (52) (53) (53) (53) (50)
Liver (53) (53) (53) (53) (51)
Cholangiocarcinoma 2 (4%) 5 (9%) 5 (10%)
Cholangiocarcinoma, Multiple 2 (4%) 4 (8%)
Hepatocellular Adenoma 1 (2%) 1 (2%) 1 (2%) 9 (18%)
Hepatocellular Adenoma, Multiple 2 (4%)
Histiocytic Sarcoma 1 (2%)
Mesentery (1) (2) (6) (8)
Lipoma 1 (17%)
Oral Mucosa (10) (18) (19) (29) (31)
Gingival, Squamous Cell Carcinoma 1 (10%) 1 (6%) 2 (6%)
Pancreas (52) (53) (53) (53) (51)
Acinus, Adenoma 2 (4%)
Acinus, Carcinoma 1 (2%) 2 (4%)
Salivary Glands (53) (53) (53) (53) (53)
Carcinoma 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Stomach, Forestomach (53) (53) (53) (53) (52)
Page 2
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:26
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Glandular (53) (53) (53) (53) (52)
Tongue (1) (1)
Squamous Cell Carcinoma, Metastatic, Oral
Mucosa 1 (100%)
Tooth (24) (23) (27) (37) (30)
Peridontal Tissue, Fibrosarcoma 1 (4%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (53) (53) (52) (53)
Aorta, Adventitia, Carcinoma, Metastatic,
Mammary Gland 1 (2%)
Heart (53) (53) (53) (52) (53)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Schwannoma Malignant 2 (4%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (52) (53) (53) (53) (51)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Adrenal Medulla (52) (53) (53) (53) (51)
Pheochromocytoma Benign 4 (8%) 3 (6%) 4 (8%) 4 (8%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (52) (53) (53) (53) (51)
Adenoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Parathyroid Gland (50) (50) (49) (47) (52)
Adenoma 1 (2%)
Pituitary Gland (53) (53) (53) (53) (53)
Carcinoma 1 (2%)
Pars Distalis, Adenoma 28 (53%) 29 (55%) 22 (42%) 20 (38%) 10 (19%)
Thyroid Gland (53) (53) (51) (52) (51)
Bilateral, C-Cell, Adenoma 2 (4%) 2 (4%) 3 (6%) 1 (2%)
Bilateral, Follicular Cell, Carcinoma 1 (2%)
C-Cell, Adenoma 15 (28%) 8 (15%) 15 (29%) 8 (15%) 5 (10%)
C-Cell, Carcinoma 2 (4%) 1 (2%) 1 (2%)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:26
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (52) (52) (53) (53) (51)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Granulosa Cell Tumor Malignant 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Uterus (52) (53) (53) (53) (51)
Carcinoma 1 (2%) 2 (4%) 2 (4%) 1 (2%)
Hemangiosarcoma 1 (2%)
Leiomyoma 2 (4%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 3 (6%) 1 (2%) 2 (4%) 3 (6%) 2 (4%)
Polyp Stromal, Multiple 1 (2%) 1 (2%)
Schwannoma Malignant 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Cervix, Carcinoma 1 (2%)
Cervix, Squamous Cell Carcinoma 1 (2%) 1 (2%)
Serosa, Carcinoma, Metastatic, Uterus 1 (2%)
Vagina (1)
Schwannoma Malignant 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (53) (53) (53) (53)
Lymph Node (4) (1) (2) (9) (11)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (11%)
Lymph Node, Mandibular (53) (53) (53) (53) (53)
Lymph Node, Mesenteric (52) (53) (53) (53) (50)
Spleen (52) (53) (53) (53) (51)
Thymus (52) (48) (50) (53) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:26
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (53) (53) (53) (52)
Adenoacanthoma 1 (2%)
Adenolipoma 1 (2%)
Adenoma 1 (2%)
Carcinoma 5 (9%) 6 (11%) 3 (6%) 5 (9%) 1 (2%)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 21 (40%) 17 (32%) 19 (36%) 20 (38%) 15 (29%)
Fibroadenoma, Multiple 13 (25%) 10 (19%) 16 (30%) 8 (15%) 3 (6%)
Skin (53) (53) (53) (53) (53)
Fibroma 1 (2%) 2 (4%) 2 (4%) 3 (6%)
Fibrosarcoma 1 (2%) 1 (2%)
Pilomatrixoma 1 (2%)
Schwannoma Malignant 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Squamous Cell Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Fibrous Histiocytoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (53) (53) (53) (53)
Carcinoma, Metastatic, Kidney 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Granular Cell Tumor Malignant 1 (2%)
Medulloblastoma Mal 1 (2%) 1 (2%)
Oligodendroglioma Malignant 1 (2%)
Meninges, Meningioma Malignant 1 (2%)
Spinal Cord (1) (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (53) (53) (53) (53)
Alveolar/Bronchiolar Adenoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Mammary Gland 3 (6%) 1 (2%) 2 (4%)
Carcinoma, Metastatic, Uterus 1 (2%)
Carcinoma, Metastatic, Adrenal Cortex 1 (2%)
Page 5
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:26
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Cystic Keratinizing Epithelioma 2 (4%) 9 (17%)
Cystic Keratinizing Epithelioma, Multiple 11 (21%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Histiocytic Sarcoma 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Mediastinum, Carcinoma, Metastatic, Mammary
Gland 1 (2%)
Mediastinum, Fibrous Histiocytoma,
Metastatic, Skeletal Muscle 1 (2%)
Nose (53) (53) (53) (53) (53)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (53) (53) (52) (53) (53)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (52) (53) (53) (53) (51)
Hemangiosarcoma 1 (2%)
Nephroblastoma 1 (2%)
Bilateral, Renal Tubule, Carcinoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(53) *(53) *(53) *(53) *(53)
Adenolipoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 2 (4%) 1 (2%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Date: 09/29/03
Route: GAVAGE Time: 12:03:26
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 51 46 50 50 45
Total Primary Neoplasms 115 94 118 99 93
Total Animals with Benign Neoplasms 45 43 46 43 39
Total Benign Neoplasms 92 77 97 75 68
Total Animals with Malignant Neoplasms 18 14 19 21 21
Total Malignant Neoplasms 23 17 21 23 25
Total Animals with Metastatic Neoplasms 7 2 2 4 1
Total Metastatic Neoplasm 11 5 2 5 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------